Faculty of Medicine, University of Novi Sad, 21137 Novi Sad, Serbia.
Department of Medical Oncology, Oncology Institute of Vojvodina, 21204 Sremska Kamenica, Serbia.
Int J Mol Sci. 2023 Jul 21;24(14):11745. doi: 10.3390/ijms241411745.
LOXL2, a copper-dependent amine oxidase, has emerged as a promising therapeutic target in hepatocellular carcinoma (HCC). Increased LOXL2 expression in HCC has been linked with an aggressive phenotype and represents a poor prognostic factor. Here, we focus on the mechanisms through which LOXL2 orchestrates multiple oncogenic functions in HCC development. We performed a review of the current knowledge on the roles LOXL2 performs in the modulation of the HCC tumor microenvironment, formation of premetastatic niches, and epithelial-mesenchymal transition. We also highlighted the complex interplay between LOXL2 and hypoxia, angiogenesis, and vasculogenic mimicry in HCC. At the end of the review, we summarize the current LOXL2 inhibitors and discuss their potential in HCC precision treatment.
LOXL2 是一种铜依赖性胺氧化酶,已成为肝细胞癌 (HCC) 的一个有前途的治疗靶点。HCC 中 LOXL2 的表达增加与侵袭性表型有关,是预后不良的因素。在这里,我们重点研究 LOXL2 在 HCC 发展过程中协调多种致癌功能的机制。我们对 LOXL2 在调节 HCC 肿瘤微环境、前转移龛形成和上皮间质转化方面的作用的现有知识进行了综述。我们还强调了 LOXL2 与 HCC 中的缺氧、血管生成和血管生成模拟之间的复杂相互作用。在综述的最后,我们总结了目前的 LOXL2 抑制剂,并讨论了它们在 HCC 精准治疗中的潜力。